



and



or a pharmaceutically acceptable salt thereof.

12. A compound according to formula (I)



wherein X is a nucleophilically displaceable leaving group, or a pharmaceutically acceptable salt thereof.

13. ~~A method for treating a cancer in a subject suffering from such cancer, comprising administering to the subject~~ Use of a therapeutically effective amount of an immunoconjugate having a structure according to claim 3 in the manufacture of a medicament for treating a cancer in a subject suffering from such cancer.

14. ~~A method-use~~ according to claim 13, wherein the cancer is renal cancer, pancreatic cancer, ovarian cancer, lymphoma, colon cancer, mesothelioma, gastric cancer, lung cancer, prostate cancer, adenocarcinoma, liver cancer, or breast cancer.

15. A ~~method~~use according to claim 13, wherein the cancer is characterized by cancer cells that express human CD70, mesothelin, PSMA, CD19, glypican-3, B7H4, RG-1, CD22, or PTK7.
